Mechanism of artesunate on bone destruction in experimental rheumatoid arthritis based on transcriptomics and network pharmacology

• Published in: Zhongguo zhongyao zazhi Vol. 48; no. 5; p. 1343
• Main Authors: Huang, Feng-Yu, Tao, Xue-Ying, Zhu, Pan-Pan, Zhang, Xin-Zhuo, Kong, Xiang-Ying, Lin, Na, Su, Xiao-Hui
• Format: Journal Article
• Language: Chinese
• Published: China 01.03.2023
• Subjects: Animals; Artesunate - pharmacology; Artesunate - therapeutic use; Arthritis, Experimental - drug therapy; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - genetics; Network Pharmacology; Osteoclasts; Rats; Receptors, Cytokine - genetics; Receptors, Cytokine - metabolism; Receptors, Cytokine - therapeutic use; Transcriptome; transcriptomics; artesunate; network pharmacology; rheumatoid arthritis; bone destruction
• ISSN: 1001-5302
• DOI: 10.19540/j.cnki.cjcmm.20221013.403

The present study investigated the mechanism of artesunate in the treatment of bone destruction in experimental rheumatoid arthritis(RA) based on transcriptomics and network pharmacology. The transcriptome sequencing data of artesunate in the inhibition of osteoclast differentiation were analyzed to obtain differentially expressed genes(DEGs). GraphPad Prism 8 software was used to plot volcano maps and heat maps were plotted through the website of bioinformatics. GeneCards and OMIM were used to collect information on key targets of bone destruction in RA. The DEGs of artesunate in inhibiting osteoclast differentiation and key target genes of bone destruction in RA were intersected by the Venny 2.1.0 platform, and the intersection target genes were analyzed by Gene Ontology(GO)/Kyoto Encyclopedia of Genes and Genomes(KEGG) enrichment. Finally, the receptor activator of nuclear factor-κB(RANKL)-induced osteoclast differentiation model and collagen-induced arthritis(CIA) model were established. Quantitative real